Poxel SA - Asset Resilience Ratio
Poxel SA (POXEL) has an Asset Resilience Ratio of 0.00% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read POXEL total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how Poxel SA's Asset Resilience Ratio has changed over time. See Poxel SA shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Poxel SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see POXEL company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Poxel SA maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Poxel SA Industry Peers by Asset Resilience Ratio
Compare Poxel SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 1.39% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Poxel SA (2016–2023)
The table below shows the annual Asset Resilience Ratio data for Poxel SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -1.78% | €-86.00K ≈ $-100.54K |
€4.82 Million ≈ $5.64 Million |
-1.23pp |
| 2022-12-31 | -0.56% | €-193.00K ≈ $-225.64K |
€34.71 Million ≈ $40.58 Million |
-13.43pp |
| 2021-12-31 | 12.87% | €7.07 Million ≈ $8.26 Million |
€54.89 Million ≈ $64.17 Million |
-62.78pp |
| 2020-12-31 | 75.65% | €49.23 Million ≈ $57.56 Million |
€65.08 Million ≈ $76.08 Million |
+23.02pp |
| 2019-12-31 | 52.63% | €38.05 Million ≈ $44.49 Million |
€72.30 Million ≈ $84.53 Million |
-37.59pp |
| 2016-12-31 | 90.22% | €45.38 Million ≈ $53.06 Million |
€50.30 Million ≈ $58.81 Million |
-- |
About Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more